177 related articles for article (PubMed ID: 22484811)
21. [Renal involvement in multiple myeloma. Physiopathology and therapy].
Fiorini F; Napoli S; Giordano L; Castelluccio A
Minerva Urol Nefrol; 1995 Sep; 47(3):125-31. PubMed ID: 8815549
[TBL] [Abstract][Full Text] [Related]
22. Extracorporeal treatment of cast nephropathy.
Gakhar B; Kobrin S; Berns JS
Semin Dial; 2011; 24(1):9-11. PubMed ID: 21324000
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy.
Rousseau-Gagnon M; Agharazii M; De Serres SA; Desmeules S
PLoS One; 2015; 10(10):e0140463. PubMed ID: 26466100
[TBL] [Abstract][Full Text] [Related]
24. The use of medium cutoff dialyzers in patients with multiple myeloma and acute kidney injury requiring hemodialysis: A systematic review.
Koniman R; Teo SH; Kaushik M; Nagarajan C; Tan MSY; Tan HK; Ramirez MEG; Lim CC;
Semin Dial; 2023 Jan; 36(1):12-17. PubMed ID: 35840146
[TBL] [Abstract][Full Text] [Related]
25. Crystalline appearance in light chain cast nephropathy is associated with higher early mortality in patients with newly diagnosed multiple myeloma.
Lin ZS; Zhang X; Yu XJ; Wang S; Wang SX; Dong YJ; Zhou FD; Zhao MH
Int Immunopharmacol; 2021 Sep; 98():107875. PubMed ID: 34146864
[TBL] [Abstract][Full Text] [Related]
26. [Management of Cast Nephropathy].
De Simone E; Fenoglio R; Cortazzi S; Careddu A; Geraci G; Bugliosi F; Sciascia S; Roccatello D
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007838
[TBL] [Abstract][Full Text] [Related]
27. Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation.
Huang ZQ; Kirk KA; Connelly KG; Sanders PW
J Clin Invest; 1993 Dec; 92(6):2975-83. PubMed ID: 8254051
[TBL] [Abstract][Full Text] [Related]
28. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.
Hutchison CA; Batuman V; Behrens J; Bridoux F; Sirac C; Dispenzieri A; Herrera GA; Lachmann H; Sanders PW;
Nat Rev Nephrol; 2011 Nov; 8(1):43-51. PubMed ID: 22045243
[TBL] [Abstract][Full Text] [Related]
29. Crystals, crystals everywhere but not a clue till late… Light chain crystalline proximal tubulopathy with concomitant myeloma cast nephropathy.
Matthai SM; Alexander S; Jacob S; Duhli N; David VG; Varughese S
Indian J Pathol Microbiol; 2020; 63(3):463-466. PubMed ID: 32769341
[TBL] [Abstract][Full Text] [Related]
30. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies.
Leboulleux M; Lelongt B; Mougenot B; Touchard G; Makdassi R; Rocca A; Noel LH; Ronco PM; Aucouturier P
Kidney Int; 1995 Jul; 48(1):72-9. PubMed ID: 7564094
[TBL] [Abstract][Full Text] [Related]
31. Use of continuous venovenous hemofiltration for acute renal failure due to multiple myeloma cast nephropathy.
Mehta S; Shtaynberg N; Goldman M; Asti D; Kiroycheva M; Pepe J
Hematology; 2012 Jul; 17(4):229-31. PubMed ID: 22889516
[TBL] [Abstract][Full Text] [Related]
32. Prolonged hemodialysis for acute kidney injury in myeloma patients.
Hanf W; Guillaume C; Jolivot A; Chapuis-Cellier C; Guebre-Egziabher F; Fontana A; Fouque D; Juillard L
Clin Nephrol; 2010 Oct; 74(4):319-22. PubMed ID: 20875387
[TBL] [Abstract][Full Text] [Related]
33. Effective Removal of κ-Free Light Chains with Hemodialysis Using Fresenius Ultraflux® EMiC®2 Dialyser in a Patient with Myeloma Cast Nephropathy, with Associated Cost Savings.
Jayaballa M; Bose B; Gangadharan Komala M; Fischer ER; Taper J; Sud K
Blood Purif; 2016; 42(2):158-9. PubMed ID: 27270690
[No Abstract] [Full Text] [Related]
34. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
Hutchison CA; Cockwell P; Reid S; Chandler K; Mead GP; Harrison J; Hattersley J; Evans ND; Chappell MJ; Cook M; Goehl H; Storr M; Bradwell AR
J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909
[TBL] [Abstract][Full Text] [Related]
35. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
[TBL] [Abstract][Full Text] [Related]
36. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.
Hutchison CA; Cockwell P; Stringer S; Bradwell A; Cook M; Gertz MA; Dispenzieri A; Winters JL; Kumar S; Rajkumar SV; Kyle RA; Leung N
J Am Soc Nephrol; 2011 Jun; 22(6):1129-36. PubMed ID: 21511832
[TBL] [Abstract][Full Text] [Related]
37. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney.
Basnayake K; Cheung CK; Sheaff M; Fuggle W; Kamel D; Nakoinz S; Hutchison CA; Cook M; Stoves J; Bradwell AR; Cockwell P
J Clin Pathol; 2010 Oct; 63(10):884-7. PubMed ID: 20876319
[TBL] [Abstract][Full Text] [Related]
38. Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury: a Case Series.
Menè P; Giammarioli E; Fofi C; Antolino G; Verde G; Tafuri A; Punzo G; Festuccia F
Kidney Blood Press Res; 2018; 43(4):1263-1272. PubMed ID: 30078004
[TBL] [Abstract][Full Text] [Related]
39. Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone.
Hada R; Poudyal B; Sharma A; Khatri R
JNMA J Nepal Med Assoc; 2012; 52(188):192-5. PubMed ID: 23591252
[TBL] [Abstract][Full Text] [Related]
40. Combined proximal tubulopathy, crystal-storing histiocytosis, and cast nephropathy in a patient with light chain multiple myeloma.
Wu CK; Yang AH; Lai HC; Lin BS
BMC Nephrol; 2017 May; 18(1):170. PubMed ID: 28545410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
